Analysts’ Viewpoint on India Human Microbiome Market Scenario
Human microbiome research has progressed from basic science to advanced therapeutics in the past few years. Following the realization of the potential role of microbiome research in human health, several government agencies and major pharmaceutical companies around the world have launched several megaprojects. Human microbiome research is still in its infancy in India; much work remains to be done to comprehend and investigate the role of microbiota in shaping overall health and disease conditions. In the past few years, introduction of new molecular technologies such as transcriptomics, metagenomics, and metabolomics has contributed to the advancement in microbiome linked to humans. These rapidly evolving technologies are increasing our knowledge about human body-associated microbiome and its relationship with human health.
The use of ‘‘India Human Microbiome’’ or regenerative therapies in orthopedic surgery has grown in recent years. Particular interest has been raised with regard to platelet-rich plasma, bone marrow aspirate, adipose-derived cells, and amniotic cells.
The use of ‘‘India Human Microbiome’’ or regenerative therapies in orthopedic surgery has grown in recent years. Particular interest has been raised with regard to platelet-rich plasma, bone marrow aspirate, adipose-derived cells, and amniotic cells. he use of ‘‘India Human Microbiome’’ or regenerative therapies in orthopedic surgery has grown in recent years. Particular interest has been raised with regard to platelet-rich plasma, bone marrow aspirate, adipose-derived cells, and amniotic cells.
Trillions of microbes, or bacteria, live in the human body. Most of these are beneficial, but can be harmful when out of balance. The terms microbiota and microbiome are used interchangeably. Microbiota is a diverse community of bacteria, viruses, fungi, and other microorganisms found in a specific environment such as the human digestive tract. Human biome refers to the body's entire habitat that includes microorganisms, genomes, and environmental conditions.
Prevotella, Ruminococcus, Bacteroides, and Firmicutes are large families of bacteria found in human gut microbiome. Peptostreptococcus, Bifidobacterium, Lactobacillus, and Clostridium are anaerobic bacteria found in the colon, which have low oxygen levels. These microbes prevent uncontrolled growth of harmful bacteria, as they compete for nutrients and attachment sites on mucus membranes of the gut – a major site of immune activity and antimicrobial protein production.
According to the India human microbiome market analysis, the probiotic industry in the country is growing at a steady pace and has the potential to advance at a rapid pace in the near future. The industry has been expanding after the introduction of various pharmaceutical probiotic formulations in the market. Incidence of chronic diseases such as diabetes, non-alcoholic fatty liver disease, coronary artery disease, numerous chronic inflammatory disorders with an immune basis, and some types of cancer is on the rise in India due to the sedentary lifestyle of the people.
Request a sample to get extensive insights into the India Human Microbiome Market
India provides a unique scenario for human microbiome research. Anthropologists and geneticists have been fascinated for decades by the enormous diversity in genetic composition, dietary habits, and ethnicity in India. Studies of human gut microbiome in the Indian population would help understand how the gut microbiome changes in the presence of various diseases and the potential effects these changes may have on human health. Additionally, R&D in human gut microbiome is likely to reveal novel information about various topics such as genetics, cultural affinities, dietary practices, and changing lifestyles.
The Government of India has taken initiatives to develop research studies on human microbiome diseases. The Human Microbiome Project (HMP) is a joint effort of public and private research institutes and universities across the country, including the All India Institute of Medical Sciences in New Delhi, the Institute of Advanced Study in Science and Technology in Guwahati, and Symbiosis International University in Pune. The National Centre for Microbial Resource (NCMR) in Pune, a part of National Centre for Cell Science, is leading the research.
In terms of product & services, the product segment held significant share of the India human microbiome market in 2021. The segment has been split into prebiotics, probiotics, drugs, and others. Increase in demand for probiotic products is expected to fuel the India human microbiome market size during the forecast period. Rise in number of working women and increase in emphasis on improving women’s health are also propelling the adoption of specialized probiotics such as Lactobacillus acidophilus, Lactobacillus rhamnosus, and Bifidobacterium.
Surge in demand for probiotic curd, yogurt, and drinks in convenient, portable, and flexible packaging materials is expected to fuel the India human microbiome market during the forecast period. Consumption of probiotic food products in India has been increasing, as many people are preferring healthy food alternatives.
Request a custom report on India Human Microbiome Market
The gastrointestinal disorders segment accounted for the largest India human microbiome market share in 2021. Growth of the segment can be ascribed to the high prevalence of various gastrointestinal ailments and increase in awareness about these ailments. Clostridioides difficile (C. difficile) is a major nosocomial pathogen that infects human gastrointestinal tract and causes diarrhea. Antibiotics treatment, which disrupts the normal gut microbiota, is a major risk factor. Human gut microbiome plays a vital role in the Clostridium Difficile infection treatment. Lactobacillus-based probiotics are used to prevent the onset of Antibiotic-associated Diarrhea (AAD) and C. difficile infection in humans.
Probiotics improve gut health and boost immunity. The geriatric population is more prone to chronic gastrointestinal disorders. Thus, increase in geriatric population and the subsequent demand for probiotics is driving the gastrointestinal disorders segment. Demand for microbiome is propelled by a shift in preference of consumers from a high-calorie diet to functional foods and beverages. Additionally, there is significant increase in burden of gastrointestinal (GI) and liver diseases along with gut microbiome studies in India. These factors are also likely to drive the gastrointestinal disorders segment during the forecast period.
The India human microbiome market is consolidated, with the presence of a small number of leading players. Expansion of product portfolio and mergers and acquisitions are key strategies adopted by leading players in the market. Unique Biotech, OptiBiotix Health Plc., Tata Chemicals Ltd., Bione, Illumina, Inc., Charles River Laboratories, QIAGEN, and Allianz Biosciences Pvt. Ltd. (ABPL) are prominent players operating in the India human microbiome market.
Each of these players has been profiled in the India human microbiome market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
Market Size Value in 2021
US$ 139.1 Mn
Market Forecast Value in 2031
More than US$ 282 Mn
Historical Data Available for
US$ Mn for Value
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Electronic (PDF) + Excel
Available upon request
Available upon request
The India human microbiome market was valued at US$ 139.1 Mn in 2021.
The India human microbiome market is projected to reach more than US$ 282.0 Mn by 2031.
The India human microbiome market is anticipated to grow at a CAGR of 6.9% from 2022 to 2031.
Increase in proactive research on gut microbiota is driving India human microbiome market.
Unique Biotech, OptiBiox Health plc, Tata Chemicals Ltd., Bione, Illumina, Inc., Charles River Laboratories, and QIAGEN.
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: India Human Microbiome Market
4. Market Overview
4.1.1. Segment Definition
4.3. Market Dynamics
4.4. India Human Microbiome Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Microbiome Therapeutics Pipeline Scenario
5.2. Regulatory Scenario
5.3. Impact of human microbiome therapeutics on current treatment options
5.4. Key Mergers & Acquisitions
5.5. COVID-18 Impact on the Human Microbiome Market
6. India Human Microbiome Market Analysis and Forecast, By Product & Services
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product & Services, 2017–2031
6.3.2. Services (Diagnostics/Sequencing)
220.127.116.11. 16s rRNA Sequencing
18.104.22.168. Metagenomic Sequencing
6.4. Market Attractiveness Analysis, by Product Type
7. India Human Microbiome Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Indication, 2017–2031
7.3.1. Gastrointestinal Disorders
7.3.2. Metabolic Disorders
7.3.3. Women's Health Disorders
7.3.4. Skin Disorders
7.4. Market Attractiveness Analysis, by Indication
8. Competition Landscape
8.1. Market Player - Competitive Matrix (by tier and size of companies)
8.2. Market Share Analysis, by Company (2021)
8.3. Company Profiles
8.3.1. Unique Biotech
22.214.171.124. Company Overview
126.96.36.199. Product Portfolio
188.8.131.52. SWOT Analysis
184.108.40.206. Financial Overview
220.127.116.11. Strategic Overview
8.3.2. Allianz Biosciences Pvt. Ltd. (ABPL)
18.104.22.168. Company Overview
22.214.171.124. Product Portfolio
126.96.36.199. SWOT Analysis
188.8.131.52. Financial Overview
184.108.40.206. Strategic Overview
8.3.3. OptiBiox Health plc
220.127.116.11. Company Overview
18.104.22.168. Product Portfolio
22.214.171.124. SWOT Analysis
126.96.36.199. Financial Overview
188.8.131.52. Strategic Overview
8.3.4. Tata Chemicals Ltd.
184.108.40.206. Company Overview
220.127.116.11. Product Portfolio
18.104.22.168. SWOT Analysis
22.214.171.124. Financial Overview
126.96.36.199. Strategic Overview
188.8.131.52. Company Overview
184.108.40.206. Product Portfolio
220.127.116.11. SWOT Analysis
18.104.22.168. Financial Overview
22.214.171.124. Strategic Overview
8.3.6. Illumina, Inc.
126.96.36.199. Company Overview
188.8.131.52. Product Portfolio
184.108.40.206. SWOT Analysis
220.127.116.11. Financial Overview
18.104.22.168. Strategic Overview
8.3.7. Charles River Laboratories.
22.214.171.124. Company Overview
126.96.36.199. Product Portfolio
188.8.131.52. SWOT Analysis
184.108.40.206. Financial Overview
220.127.116.11. Strategic Overview
18.104.22.168. Company Overview
22.214.171.124. Product Portfolio
126.96.36.199. SWOT Analysis
188.8.131.52. Financial Overview
184.108.40.206. Strategic Overview
8.3.9. Other Prominent Players
220.127.116.11. Company Overview
18.104.22.168. Product Portfolio
22.214.171.124. SWOT Analysis
126.96.36.199. Financial Overview
188.8.131.52. Strategic Overview
List of Tables
Table 01: Human Microbiome Market Value (US$ Mn) Forecast, by Product & Service, 2017–2031
Table 02: Human Microbiome Market Value (US $ Mn) Forecast, by Product, 2017–2031
Table 03: Human Microbiome Market Value (US $ Mn) Forecast, by Service (Diagnostics/Sequencing), 2017–2031
Table 04: Human Microbiome Market Size (US$ Mn) Forecast, by Indication, 2017–2031
List of Figures
Figure 01: Human Microbiome Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Human Microbiome Market Value Share Analysis, by Product & Service, 2021 and 2031
Figure 03: Human Microbiome Market Attractiveness Analysis, by Product & Service, 2022–2031
Figure 04: Human Microbiome Market Revenue (US$ Mn), by Product, 2017–2031
Figure 05: Human Microbiome Market Revenue (US$ Mn), by Service (Diagnostics/Sequencing), 2017–2031
Figure 06: Human Microbiome Market Value Share Analysis, by Indication, 2021 and 2031
Figure 07: Human Microbiome Market Attractiveness Analysis, by Indication, 2022–2031
Figure 08: Human Microbiome Market Revenue (US$ Mn), by Gastrointestinal Disorders, 2017–2031
Figure 09: Human Microbiome Market Revenue (US$ Mn), by Metabolic Disorders, 2017–2031
Figure 10: Human Microbiome Market Revenue (US$ Mn), by Women's Health Disorders, 2017–2031
Figure 11: Human Microbiome Market Revenue (US$ Mn), by Skin Disorders, 2017–2031
Figure 12: Human Microbiome Market Revenue (US$ Mn), by Others, 2017–2031